In this context, recent studies showed the CXCL12 antagonist (AMD3100) or CXCR4 antagonist (T140) cause sensitization of MM cells to novel and standard chemotherapy agents by blocking the CXCL12/CXCR4 downstream signaling [36], [37]. This evidence concerns the gene CXCR4 and Miyoshi myopathy.